A Flori­da man al­leged­ly set up an il­lic­it net­work of drug whole­sale op­er­a­tions in the US and used them to har­vest $230 mil­lion from the sale of adul­ter­at­ed and mis­la­beled HIV meds.

Ac­cord­ing to the US De­part­ment of Jus­tice, 51-year-old Lazaro Her­nan­dez was charged with ob­tain­ing a large sup­ply of HIV meds il­le­gal­ly, then cre­at­ing false drug la­bels and doc­u­ments to make it pos­si­ble to sell them at a deep dis­count to co-con­spir­a­tors at “whole­sale phar­ma­ceu­ti­cal dis­trib­u­tors in Mis­sis­sip­pi, Mary­land, and New York.”

The drugs were then sold to phar­ma­cies and billed back to a num­ber of in­sur­ers, in­clud­ing Medicare. Says the DOJ:

As al­leged in the in­dict­ment, be­tween ap­prox­i­mate­ly 2019 and 2021, the whole­sale phar­ma­ceu­ti­cal dis­trib­u­tors paid Her­nan­dez and his co-con­spir­a­tors more than $230 mil­lion for the il­le­gal­ly ac­quired and adul­ter­at­ed pre­scrip­tion drugs. Her­nan­dez al­leged­ly laun­dered those hun­dreds of mil­lions of dol­lars through the use of sev­er­al cor­po­ra­tions in Mi­a­mi.

Now Her­nan­dez is fac­ing a laun­dry list of charges cov­er­ing false doc­u­men­ta­tion, mon­ey laun­der­ing and a con­spir­a­cy to de­liv­er adul­ter­at­ed and mis­la­beled drugs. Al­to­geth­er, he faces more than 100 years in prison. He was al­so in­dict­ed by a grand ju­ry in Mi­a­mi a few days ago.

Two weeks ago, Biohaven hit an all-time high in weekly Nurtec prescriptions. CEO Vlad Coric attributes at least some of that success to a new interactive Twitter campaign that encourages patients to free their feed of potential migraine triggers.

Earlier this month, Biohaven in partnership with Twitter launched the #RelieveYourFeed campaign that allows users to customize their app settings based on their migraine triggers.

Over the past few months, oncologists have been talking a lot about the ASCO conference. Not surprising considering its import and the study data presented, but what may be less expected is the second most talked about topic of health equity.

That’s according to data from The Harris Poll and the new expert network the researcher is building out. While the company has been doing deep data dives into specific health issues or conditions for pharma clients, it’s now monitoring influencer networks of therapy area specialists to find out what experts are really thinking about.

The rise of pharma environmental, social and governance (ESG) efforts in the past two years has been meteoric as investors turn their attention to sustainable funding. However, investors aren’t the only ones watching. Patients are beginning to tune into pharmas’ ESG promises too.

Patient advocacy groups familiar with ESG regard it as an important issue and want to be included in helping pharma companies set ESG policies and targets, according to a new report from PatientView. That’s quite different from what the investment community wants across a variety of Gartner’s defined financial, competitive, strategic and perception goals.

Lonza has been expanding its reach across the globe, bringing sites in China and the US online this year, but now they are looking closer to home for their next major investment.

The Swiss manufacturer on Friday announced plans to construct a large-scale commercial drug fill and finish facility in the town of Stein, Switzerland. The new facility will be delivered through an investment of approximately CHF 500 million, or $519 million, and is expected to be completed in 2026. The facility will also be constructed on the same campus as Lonza’s current clinical drug product facility.